News
EDSA
5.42
+6.07%
0.31
Weekly Report: what happened at EDSA last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at EDSA last week (0708-0712)?
Weekly Report · 07/15 10:45
Weekly Report: what happened at EDSA last week (0701-0705)?
Weekly Report · 07/08 10:47
Weekly Report: what happened at EDSA last week (0624-0628)?
Weekly Report · 07/01 10:47
Edesa Biotech Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 06/28 11:44
HC Wainwright & Co. Reiterates Buy on Edesa Biotech, Maintains $21 Price Target
Benzinga · 06/28 11:33
Promising Outlook for Edesa Biotech’s Paridiprubart: A Buy Rating Justified by BARDA-Backed ARDS Study and Broad Therapeutic Potential
TipRanks · 06/28 10:17
Edesa Biotech’s ARDS Drug Chosen for US Trial
TipRanks · 06/24 12:51
EDESA BIOTECH INC: BARDA SELECTS CO'S DRUG FOR U.S. FUNDED PLATFORM TRIAL IN GENERAL ARDS
Reuters · 06/24 12:22
BARDA Selects Edesa Biotech's Paridiprubart For U.S. Funded Platform Trial In General ARDS
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome. The BARDA-funded project is expected to complement Edesa's drug development activities in COVID-19 ARDS. Edesa Biotech's first-in-class drug candidate has been selected for evaluation in a U.S. Government-funded clinical study.
Benzinga · 06/24 12:22
Weekly Report: what happened at EDSA last week (0617-0621)?
Weekly Report · 06/24 10:53
Weekly Report: what happened at EDSA last week (0610-0614)?
Weekly Report · 06/17 10:46
Weekly Report: what happened at EDSA last week (0603-0607)?
Weekly Report · 06/10 10:48
Weekly Report: what happened at EDSA last week (0527-0531)?
Weekly Report · 06/03 10:50
Edesa Biotech Shareholders Approve Board and Compensation Plans
TipRanks · 05/30 22:01
Weekly Report: what happened at EDSA last week (0520-0524)?
Weekly Report · 05/27 10:54
Weekly Report: what happened at EDSA last week (0513-0517)?
Weekly Report · 05/20 10:48
Weekly Report: what happened at EDSA last week (0506-0510)?
Weekly Report · 05/13 10:56
Edesa Biotech, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024
Press release · 05/11 07:09
EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024
Edena Biotech reported earnings per share of -58 cents for the second quarter of 2024. The company did not report any revenue for the quarter. Edesa Biotech's earnings were above the analyst estimate for -69 cents per share. The company just reported results.
Investorplace · 05/11 00:53
More
Webull provides a variety of real-time EDSA stock news. You can receive the latest news about Edesa Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDSA
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.